Comparison of safety and efficacy of convalescent plasma with fresh frozen plasma in severe covid-19 patients.
An Acad Bras Cienc
; 94(4): e20210202, 2022.
Article
en En
| MEDLINE
| ID: mdl-36102392
ABSTRACT
BACKGROUND:
Role of Convalescent plasma (COPLA) to treat severe COVID-19 is under investigation. We compared efficacy and safety of COPLA with fresh frozen plasma (FFP) in severe COVID-19 patients.METHODS:
One group received COPLA with standard medical care (n = 14), and another group received random donor FFP, as control with standard medical care (n = 15) in severe COVID-19 disease.RESULTS:
The proportion of patients free of ventilation at day seven were 78.5% in COPLA group, and 93.3 % in control group were not significant (p= 0.258). However, improved respiratory rate, O2 saturation, SOFA score, and Ct value were observed in the COPLA group. No serious adverse events were noticed by plasma transfusion in both groups.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Plasma
/
COVID-19
Tipo de estudio:
Clinical_trials
Límite:
Humans
Idioma:
En
Revista:
An Acad Bras Cienc
Año:
2022
Tipo del documento:
Article
País de afiliación:
India